About bayer ag - BAYZF
Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.
BAYZF At a Glance
Bayer AG
Kaiser-Wilhelm-Allee 1
Leverkusen, Nordrhein-Westfalen 51368
| Phone | 49-214-30-1 | Revenue | 51.43B | |
| Industry | Pharmaceuticals: Major | Net Income | -4,085,452,181.14 | |
| Sector | Health Technology | 2025 Sales Growth | 2.027% | |
| Fiscal Year-end | 12 / 2026 | Employees | 88,078 | |
| View SEC Filings |
BAYZF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.83 |
| Price to Book Ratio | 1.401 |
| Price to Cash Flow Ratio | 8.28 |
| Enterprise Value to EBITDA | 6.245 |
| Enterprise Value to Sales | 1.508 |
| Total Debt to Enterprise Value | 0.567 |
BAYZF Efficiency
| Revenue/Employee | 583,970.346 |
| Income Per Employee | -46,384.479 |
| Receivables Turnover | 3.593 |
| Total Asset Turnover | 0.408 |
BAYZF Liquidity
| Current Ratio | 0.996 |
| Quick Ratio | 0.616 |
| Cash Ratio | 0.241 |
BAYZF Profitability
| Gross Margin | 59.206 |
| Operating Margin | 15.258 |
| Pretax Margin | -6.769 |
| Net Margin | -7.943 |
| Return on Assets | -3.244 |
| Return on Equity | -12.865 |
| Return on Total Capital | -5.488 |
| Return on Invested Capital | -5.937 |
BAYZF Capital Structure
| Total Debt to Total Equity | 144.302 |
| Total Debt to Total Capital | 59.067 |
| Total Debt to Total Assets | 33.852 |
| Long-Term Debt to Equity | 122.604 |
| Long-Term Debt to Total Capital | 50.185 |
Bayer Ag in the News
How Roundup lawsuits could give China an edge
Legal fees associated with Bayer's Roundup, a weed-killing product used by farmers and gardeners who want to protect their crops or yards, have cost the company significantly.
Western drugmakers are still providing medicines to Russia
Western health care companies continue supplying medicine, vaccines and medical equipment to Russia.
Biden pushes Congress to allow Medicare to negotiate drug prices
President Biden is set to lay out his vision Thursday for reducing the high cost of prescription drugs, and is expected to push Congress to pass legislation that would allow Medicare to negotiate drug prices for millions of Americans.